Engineered nasal cartilage by cell homing: a model for augmentative and reconstructive rhinoplasty

Mendelson A, Ahn JM, Paluch K, Embree MC, Mao JJ.

PubMed 24867716 Publisher (DOI)Free full text (PMC)

What this paper says

In a rat model, a scaffold releasing a growth factor drew the animal's own cells in and grew cartilage like tissue on the nasal bridge over ten weeks, in proportion to the dose.

Overview

Building up a nose currently means taking cartilage from the patient, which causes donor site problems, or using a synthetic implant, which can look unnatural and can become infected or shift. This laboratory study tested a third route: implanting a scaffold that recruits the body's own cells and pushes them to become cartilage. The work was done in rats, not people.

Sections of note

Animal study. A rat model of augmentation rhinoplasty was made by scoring the surface of the native nasal cartilage and implanting a scaffold on top.
The scaffold was bilayered: gelatin microspheres containing alginate and a cytokine, sitting on a porous poly lactic-co-glycolic acid base.
Microspheres carried recombinant human transforming growth factor beta 3 at 200, 500 or 1000 nanograms; control microspheres carried phosphate buffered saline only.
Tissue formation was assessed by image analysis and by staining with hematoxylin and eosin, toluidine blue, Verhoeff elastic van Gieson and aggrecan immunohistochemistry.
Sustained release over the tested 10 weeks produced cartilage like tissue at the implant site, increasing with dose.
The authors state this is the first attempt to engineer cartilage for rhinoplasty by cell homing.

What it means for a patient

This is early laboratory work in animals. No human has been treated with this method in this study.
The aim is a graft that does not require cutting cartilage from the rib, ear or septum.
No safety data, durability beyond ten weeks, or shape control results are reported.
Nothing here changes current choices between the patient's own cartilage and synthetic implants.

Why this paper matters

Donor site cost and implant failure are the two persistent weaknesses of augmentation rhinoplasty, and cell homing attacks both. Whether the approach can build enough tissue, in a controlled shape, and hold it in humans is unanswered.

Terms

Cell homing: attracting the body's own cells into an implanted scaffold rather than seeding cells in a laboratory.
Scaffold: a porous structure implanted to give new tissue a framework to grow on.
Chondrogenesis: the process by which cells turn into cartilage.
Transforming growth factor beta 3: a signalling protein that drives cells toward cartilage.
Autologous graft: tissue taken from the patient's own body.

Summary written by rhinoplasty.cc from the abstract, 2026-09-08; not medical advice. The authors' own abstract follows.

Abstract

Background: Current augmentative and reconstructive rhinoplasties use auto logous tissue grafts or synthetic bioinert materials to repair nasal trauma or attain an aesthetic shape. Autologous grafts are associated with donor-site trauma and morbidity. Synthetic materials are widely used but often yield an unnatural appearance and are prone to infection or dislocation. There is an acute clinical need for the generation of native tissues to serve as rhinoplasty grafts without the undesirable features that are associated with autologous grafts or current synthetic materials.

Methods: Bioactive scaffolds were developed that not only recruited cells in the nasal dorsum in vivo, but also induced chondrogenesis of the recruited cells. Bilayered scaffolds were fabricated with alginate-containing gelatin microspheres encapsulating cytokines atop a porous poly(lactic-co-glycolic acid) base. Microspheres were fabricated to contain recombinant human transforming growth factor-β3 at doses of 200, 500, or 1000 ng, with phosphate-buffered saline-loaded microspheres used as a control. A rat model of augmentation rhinoplasty was created by implanting scaffolds atop the native nasal cartilage surface that was scored to induce cell migration. Tissue formation and chondrogenesis in the scaffolds were evaluated by image analysis and histologic staining with hematoxylin and eosin, toluidine blue, Verhoeff elastic-van Geison, and aggrecan immunohistochemistry.

Results: Sustained release of increasing doses of transforming growth factor-β3 for up to the tested 10 weeks promoted orthotopic cartilage-like tissue formation in a dose-dependent manner.

Conclusions: These findings represent the first attempt to engineer cartilage tissue by cell homing for rhinoplasty, and could potentially serve as an alternative material for augmentative and reconstructive rhinoplasty.

Abstract as indexed by PubMed; the article is open access (PubMed Central).